高剂量与标准剂量每日两次胸部放疗治疗局限期小细胞肺癌:开放标签随机2期试验
这项开放标签随机2期试验在挪威、丹麦和瑞典的22家公立医院纳入176例局限期小细胞肺癌患者,随机接受60 Gy/40次或45 Gy/30次每日两次胸部放疗。
要点
- 60 Gy每日两次胸部放疗较45 Gy显著提高2年总生存率。
- 两组≥3级不良事件及治疗相关死亡相似。
- 60 Gy每日两次方案可作为局限期小细胞肺癌的替代放疗方案。
核心结论
- 60 Gy每日两次胸部放疗较45 Gy显著改善局限期小细胞肺癌的2年总生存,且未增加毒性。
研究设计与样本
- 开放标签、随机、2期试验,在挪威、丹麦和瑞典22家公立医院开展。
- 2014年7月8日至2018年6月6日入组176例,170例随机分配至60 Gy组(n=89)或45 Gy组(n=81)。
- 入组条件为≥18岁、初治确诊局限期小细胞肺癌、ECOG评分0-2、RECIST v1.1可测量病灶。
- 所有患者接受4周期顺铂75 mg/m2或卡铂(AUC 5-6 mg/mL×min)联合依托泊苷100 mg/m2化疗,每3周一次。
- 放疗于首周期化疗后20-28天开始,每日两次、每周10次,序贯预防性颅脑照射25-30 Gy。
主要发现
- 最常见3-4级不良事件为中性粒细胞减少(60 Gy组72/89例[81%] vs 45 Gy组62/77例[81%])、中性粒细胞减少性感染(24[27%] vs 30[39%])、血小板减少(21[24%] vs 19[25%])、贫血(14[16%] vs 15[20%])和食管炎(19[21%] vs 14[18%])。
- 60 Gy组38例发生55起严重不良事件,45 Gy组44例发生56起。
- 每组各有3例治疗相关死亡。
关键数值与推荐
- 放疗剂量与分割:60 Gy/40次/每日两次 vs 45 Gy/30次/每日两次,每周10次。
- 化疗方案:顺铂75 mg/m2或卡铂AUC 5-6 mg/mL×min,联合依托泊苷100 mg/m2,每3周一次,共4周期。
临床怎么用
- 对于局限期小细胞肺癌,每日两次胸部放疗60 Gy/40次可作为45 Gy/30次的替代方案。
- 该方案在未增加毒性的前提下显著改善2年生存,支持临床选择高剂量每日两次放疗。
- 治疗实施需注意放疗与化疗的时序(首周期化疗后20-28天开始放疗)。
局限性
- 本研究为2期试验,样本量170例,结论需3期试验验证。
- 开放标签设计可能引入偏倚。
- 随访仍在进行中,长期生存数据尚未成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concurrent chemoradiotherapy is standard treatment for limited stage small-cell lung cancer (SCLC). Twice-daily thoracic radiotherapy of 45 Gy in 30 fractions is considered to be the most effective schedule. The aim of this study was to investigate whether high-dose, twice-daily thoracic radiotherapy of 60 Gy in 40 fractions improves survival. METHODS: This open-label, randomised, phase 2 trial was done at 22 public hospitals in Norway, Denmark, and Sweden. Patients aged 18 years and older with treatment-naive confirmed limited stage SCLC, Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and measurable disease according to the Response Evaluation Criteria in Solid Tumors version 1.1 were eligible. All participants received four courses of intravenous cisplatin 75 mg/m2 or carboplatin (area under the curve 5-6 mg/mL × min, Calvert's formula) on day 1 and intravenous etoposide 100 mg/m2 on days 1-3 every 3 weeks. Participants were randomly assigned (1:1) in permuted blocks (sized between 4 and 10) stratifying for ECOG performance status, disease stage, and presence of pleural effusion to receive thoracic radiotherapy of 45 Gy in 30 fractions or 60 Gy in 40 fractions to the primary lung tumour and PET-CT positive lymph node metastases starting 20-28 days after the first chemotherapy course. Patients in both groups received two fractions per day, ten fractions per week. Responders were offered prophylactic cranial irradiation of 25-30 Gy. The primary endpoint, 2-year overall survival, was assessed after all patients had been followed up for a minimum of 2 years. All randomly assigned patients were included in the efficacy analyses, patients commencing thoracic radiotherapy were included in the safety analyses. Follow-up is ongoing. This trial is registered at ClinicalTrials.gov, NCT02041845. FINDINGS: Between July 8, 2014, and June 6, 2018, 176 patients were enrolled, 170 of whom were randomly assigned to 60 Gy (n=89) or 45 Gy (n=81). Median follow-up for the primary analysis was 49 months (IQR 38-56). At 2 years, 66 (74·2% [95% CI 63·8-82·9]) patients in the 60 Gy group were alive, compared with 39 (48·1% [36·9-59·5]) patients in the 45 Gy group (odds ratio 3·09 [95% CI 1·62-5·89]; p=0·0005). The most common grade 3-4 adverse events were neutropenia (72 [81%] of 89 patients in the 60 Gy group vs 62 [81%] of 77 patients in the 45 Gy group), neutropenic infections (24 [27%] vs 30 [39%]), thrombocytopenia (21 [24%] vs 19 [25%]), anaemia (14 [16%] vs 15 [20%]), and oesophagitis (19 [21%] vs 14 [18%]). There were 55 serious adverse events in 38 patients in the 60 Gy group and 56 serious adverse events in 44 patients in the 45 Gy group. There were three treatment-related deaths in each group (one neutropenic fever, one aortic dissection, and one pneumonitis in the 60 Gy group; one thrombocytic bleeding, one cerebral infarction, and one myocardial infarction in the 45 Gy group). INTERPRETATION: The higher radiotherapy dose of 60 Gy resulted in a substantial survival improvement compared with 45 Gy, without increased toxicity, suggesting that twice-daily thoracic radiotherapy of 60 Gy is an alternative to existing schedules. FUNDING: The Norwegian Cancer Society, The Liaison Committee for Education, Research and Innovation in Central Norway, the Nordic Cancer Union, and the Norwegian University of Science and Technology.
引用
- Grønberg BH, Killingberg KT, Fløtten Ø, et al. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol. 2021. PMID: 33662285. doi:10.1016/S1470-2045(20)30742-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。